Skip to content
AnecdotalExperimental GH fragment targeting fat metabolism

Frag 17-23

Also indexed as HGH Fragment 17-23, GH Frag 17-23, Growth Hormone Fragment 17-23

Frag 17-23 is a short synthetic peptide fragment derived from amino acids 17 through 23 of the human growth hormone (hGH) sequence. It is hypothesized to retain lipolytic properties similar to larger hGH fragments while being structurally distinct from the more widely studied Frag 176-191. Evidence for its efficacy in humans remains largely anecdotal, with minimal published research specific to this fragment.

Overview

Following subcutaneous administration, the peptide enters systemic circulation and is subject to rapid proteolytic degradation given its short sequence, resulting in an estimated half-life of 1–2 hours. Distribution to adipose tissue would be governed by passive diffusion and any receptor-mediated uptake. At the adipocyte level, proposed cAMP elevation would upregulate HSL activity, increasing free fatty acid mobilization into circulation. Unlike intact hGH, the fragment lacks the binding sites required for strong GH receptor dimerization and subsequent STAT5 phosphorylation, theoretically minimizing IGF-1 elevation, insulin resistance, and tissue growth side effects.

Proposed mechanism

Frag 17-23 is proposed to interact with adipocyte signaling pathways in a manner analogous to other growth hormone-derived fragments, potentially stimulating lipolysis by modulating beta-adrenergic or cAMP-dependent pathways without significantly activating the full IGF-1 axis. The peptide is thought to mimic a region of hGH responsible for fat-mobilizing activity, triggering the breakdown of stored triglycerides into free fatty acids. However, specific receptor binding data and robust mechanistic studies for this particular fragment are not well established in the peer-reviewed literature.

What the evidence supports

Evidence rests primarily on self-reported experience. Controlled studies are lacking.

Graded Anecdotal

Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Lipolytic and antilipogenic properties of a growth hormone releasing peptide and its analogues in 3T3-L1 adipocytes

    · American Journal of Physiology - Endocrinology and Metabolism · 2005

  2. [2]

    AOD9604: An anti-obesity drug with some of the effects of growth hormone

    · Journal of Endocrinology and Metabolism (general GH fragment literature) · 2006

  3. [3]

    Growth hormone and adipose tissue: beyond the adipokines

    · Endocrine Reviews · 2010

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACTH 1-39

Clinical

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

0 RCT · 0 human · 0 preclinical

Immune

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

AICAR

Human-limited

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

0 RCT · 0 human · 0 preclinical

metabolic